|
|
|
| Expression and Clinical Significance of SIK1 and SIK2 in Thyroid Microcarcinoma and Adjacent Tissues |
| HUANG Bo, ZHENG Jian-zhong, LIU Jin-huang, et al |
| The Second Affiliated Hospital of Shenzhen University/People's Hospital of Shenzhen Baoan District,Shenzhen,Guangdong 518101 |
|
|
|
|
Abstract 【Objective】To investigate the expression and clinical significance of SIK1 (salt-induced protein kinase 1) and SIK2 (salt-induced protein kinase 2) in thyroid microcarcinoma and adjacent tissues. 【Methods】 A total of 80 cases of pathology-confirmed thyroid microcarcinoma and matched paracancerous tissues from January 2014 to December 2016 were collected from the specimens bank of thyroid cancer in Shenzhen Baoan District People's Hospital. The expression levels of SIK1 and SIK2 in thyroid microcarcinoma and adjacent tissues were detected by immunohistochemistry and Q-PCR. The correlations of gene expression with patients' age, gender, tumor diameter, TNM stage and vascular invasion were analyzed.【Results】The results of immunohistochemistry showed that the expression levels of SIK1 and SIK2 in cancer tissues were higher than those in adjacent tissues (P<0.05). The results of PCR showed that the expression level of SIK1 in cancer tissue was significantly higher than that in adjacent tissues (P<0.05). However, there was no significant difference in the expression level of SIK2 between cancer tissues and adjacent tissues (P>0.05). Logistic regression analysis showed that the expression level of SIK1 in thyroid microcarcinoma tissue was positively correlated with tumor diameter, vascular invasion, lymphatic metastasis and distant metastasis (P<0.05). Logistic regression analysis also showed that the expression level of SIK2 was positively correlated with tumor size, lymphatic metastasis and whether distant metastasis (P<0.05). 【Conclusion】The expression levels of SIK1 and SIK2 in thyroid microcarcinoma tissues are significantly higher than those in tumor adjacent tissues. The levels of SIK1 and SIK2 expression are positively correlated with tumor diameter, lymphatic metastasis and distant metastasis, suggesting that SIK1 and SIK2 are related to the progression and prognosis. SIK1 and SIK2 can be used as new indicators of thyroid microcarcinoma diagnosis and treatment.
|
|
Received: 04 March 2019
|
|
|
|
|
|
[1] 花苏榕, 孙庆贺, 张磊,等. 长径≤0.5 cm的甲状腺微小乳头状癌的临床病理特征分析[J].中华内分泌外科杂志, 2017, 11(4):316-321.
[2] 张金苹, 何一凡, 帅瑛,等. 甲状腺乳头状微小癌77例临床分析[J].中华全科医师杂志, 2017, 16(2):111-113.
[3] 王旭红, 徐晓琴, 荆结线,等. BRAFV600E基因突变与临床颈淋巴结阴性甲状腺乳头状微小癌中央区淋巴结转移的关系探讨[J].中国药物与临床, 2017, 17(9):1277-1281.
[4] 中国抗癌协会甲状腺癌专业委员会. 甲状腺微小乳头状癌诊断与治疗中国专家共识(2016版)[J].中国肿瘤临床, 2016, 43(12):526-526.
[5] 侯文群, 杨小敏. 甲状腺乳头状癌颈部淋巴结转移的研究进展[J].中国全科医学, 2016, 19(36):4533-4536.
[6] 李同昌, 王彪, 段秀庆. 单侧甲状腺微小乳头状癌对侧腺体隐匿癌灶的预测因素及手术治疗策略[J].医学研究生学报, 2017, 30(6):641-644.
[7] 李徐恩, 龚利挺. 可外科治疗甲状腺微小乳头状癌的临床病理特点研究[J].现代实用医学, 2017, 29(8):1033-1035.
[8] 肖智.乳头状甲状腺癌颈淋巴结的转移方式及相关影响因素在颈部不同区域淋巴结转移中的意义[J].中外医学研究, 2017, 15(19):45-46.
[9] 潘先均,胡代星,苏新良.颈部中央区淋巴结清扫及术中冰冻病理检查在甲状腺微小乳头状癌治疗中的临床价值[J].上海交通大学学报(医学版), 2018, 38(2):180-183.
[10] 李寅辉, 樊勇. MicroRNA与甲状腺癌的关系[J].医学综述, 2014, 20(10):1732-1734.
[11] Wehr MC, Holder MV, Gailite I,et al. Salt-inducible kinases regulate growth through the Hippo signalling pathway in Drosophila[J].Nat Cell Biol,2013, 15(1):61-71.
[12] Berdeaux R.SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes[J].Nat Med,2007, 13(5):597.
[13] Ahmed A A, Lu Z, Jennings N B, et al. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer [J].Cancer Cell,2010, 18(2):99-100.
[14] Stephenson A, Huang GY, Nguyen NT,et al. snf1lk, encodes a protein kinase that may function in cell cycle regulation[J].Genomics,2004, 83(6):1105-1115. |
|
|
|
2019, Vol. 36 
